Eli Lilly Reports 45% Revenue Growth in Q1 2025, Surpasses Novo Nordisk in U.S. GLP-1 Prescription Volume

May 02, 2025 08:47 CST Updated 08:47

Eli Lilly

Global Pharmaceutical R&D and Production Company

5Month1Date, Eli Lilly and Company Release2025Q1 Financial Report, Total Revenue127.29 Billion USD, Year-over-Year Growth45%Revenue in China4.51Billion USD, year-on-year growth20%. R&D Investment27.3billion US dollars, a year-on-year increase of8%, accounting for21.5%。

Eli Lilly defines its core products asEbglyss、Jaypirca、Kisunla、Mounjaro、Omvoh、VerzenioAndZepbound, the above-mentioned productsQ1Revenue reached75.2Billion USD (+119%), mainly byMounjaroAndZepboundSales Growth Driver.

MounjaroGlobal revenue is38.4Billion US dollars (+113%), of which the revenue from the U.S. market was26.6Billion US dollars (+75%), Total Prescription Volume (TRx`) accounted for`39%, New Prescription Volume (NBRx) accounted for46%；ZepboundSales in the U.S.23.1billion dollars, currently accounting for over60%, Proportion of New Prescriptions74%。

Overall, as of2025YearQ1Eli Lilly occupies a leading position in the U.S. incretin mimetic market, with its total prescription volume share increasing.53.3%, surpassing its competitor Novo Nordisk. Currently, Eli Lilly has passedLillyDirectExclusive Launch by Online Medical Platform7.5mgAnd10.0mgSpecificationZepboundSingle-dose vials are expected to further open up the market.

In addition, for the treatment of breast cancerCDK4/6InhibitorVerzenioIncome12.6Billion USD (+18%), accounting for a total prescription volume share of43%。JaypircaRevenue generation9200Million USD, and received EU approval for the treatment ofBTKRecurrent or Refractory After Inhibitor TreatmentCLLRegulatory approval.Eli Lilly Revenue6000"Million US dollars,"Kisunla Revenue2100Million USD;IL-23p19Monoclonal Antibodymirikizumab（Omvoh) ObtainFDAApproved for the treatment of moderate to severe active Crohn's disease in adults.

In clinical research, Eli Lilly has made several advancements: oral small moleculesGLP-1RAgonistOrforglipronTheIIIPeriodACHIEVE-1The study achieved positive results,Compared with placebo，OrforglipronIn40Reached at the same timeA1CReduce the more optimal primary endpoint, from8.0%Baseline Mean ReductionA1C 1.3%To1.6%, andOverall safety and establishedGLP-1Consistent with the class of drugs；

siRNATherapyLepodisiran IIPhase ClinicalALPACAThe study achieved positive results,LepodisiranAt the highest test dose (400mg) Treat adultsLp(a)Patients with elevated levels,Lp(a)Decreased nearly from baseline94%, reaching the primary endpoint; Baricitinib（Baricitinib）Treatment of Adolescent Alopecia AreataIIIPeriodBRAVE-AA-PEDSResearch AchievementsPositive Data。

In terms of regulation,Jaypirca（pirtobrutinib) has obtained the European Medicines Agency (EMA) Human Medicines Committee (CHMP) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL）；CHMPNot recommended for approvaldonanemabUsed to treat early Alzheimer's disease, Eli Lilly and Company will seek a re-review.

In addition, Eli Lilly hasCompletedScorpion TherapeuticsCompanySmall MoleculesPI3KαInhibitorSTX-478The Acquisition, which is currently in the pipeline for breast cancer and other advanced solid tumorsI/IIEvaluated in clinical trials.

Eli Lilly and Company expects,2025The year will have multipleIIIPhase Clinical Trials and Regulatory Progress, Full-Year Revenue GuidanceWill be in580Hundred Million~610Between billion US dollars.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.